Management of Coronary Artery Disease and Chronic Stable Angina

Yesenia Camero, PharmD, BCPS; Jinwi Ghogomu, PharmD, BCPS, CPh


US Pharmacist. 2017;42(2):27-31. 

In This Article


The primary goals of treatment for patients with SIHD are to maximize quality of life and minimize the risk of death. Risk-factor reduction can be achieved through the optimal management of diabetes, hypertension, and hyperlipidemia. Additional therapies known to reduce the incidence of cardiac events, such as aspirin, weight loss, smoking cessation, and exercise, should be implemented to manage symptoms. Beta-blockers are the preferred initial agents; however, calcium channel blockers, ranolazine, and nitrates may be used to relieve symptoms when initial beta-blocker treatment is unsuccessful or if beta-blockers are contraindicated or cause intolerable adverse effects. Understanding the role of these medications, as well as keeping abreast of the evidence supporting their use, is crucial in reducing morbidity and mortality in patients with SIHD.